Form 4: Korro Bio Director Timothy R. Pearson Acquires Stock Options

Director Timothy R. Pearson acquired stock options in Korro Bio, Inc. on June 11, 2024.

Summary

• On June 11, 2024, Timothy R. Pearson, a director of Korro Bio, Inc., acquired stock options.
• The stock options grant the right to buy 5,190 shares of common stock at an exercise price of $42.19.
• The options vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) the date of the next annual meeting of stockholders, subject to continued service as a non-employee director through the applicable vesting date.
• Following the transaction, Pearson directly owns 5,190 derivative securities.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard transaction. The director's acquisition of stock options could be interpreted as a positive signal, but it's not definitively bullish.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future prospects.

Industry Context

This is a standard SEC Form 4 filing, reflecting a change in beneficial ownership of securities by a company insider. Such filings are common and provide transparency to the market regarding insider transactions.

Comparison to Industry Standards

• Stock option grants to directors are a common form of compensation in the biotechnology industry.
• The vesting schedule and exercise price are typical for such grants.
• Comparing the size of the grant to those of directors at similar-stage biotech companies (e.g., those with similar market capitalization and pipeline development) would provide further context.

Stakeholder Impact

• The transaction may have a minor positive impact on shareholder sentiment due to the director's increased stake in the company.

Key Dates